The probe into bribery by GlaxoSmithKline (GSK) in China is complete and the case has been handed over to prosecutors, police said Wednesday.
Prosecutors have started their examination of the case that involves 46 suspects, including British national Mark Reilly, manager of GSK China, Xinhua reported.
After 10 months of investigation, police found that Reilly had ordered his subordinates to offer bribes.
Reilly allegedly pressed his sales teams to bribe hospitals, doctors, other medical institutions and organisations through various means and gained illegal revenue worth billions.
Reilly became head of prescription drugs at GSK China in Jan 2009 and was promoted to general manager of GSK China in Nov 2012.
Two other executives, Zhang Guowei and Zhao Hongyan, are also suspected of bribing officials in Beijing and Shanghai.
Police had detained four senior executives of GSK China last year in July on suspicion of commercial bribery.
GSK China's revenue in China increased from about 3.9 billion yuan (around $481.8 million) in 2009 to 6.9 billion yuan in 2012.
